hytrin 2 mg tabl.
amdipharm ltd. - terazosinehydrochloride - eq. terazosine 2 mg - tablet - 2 mg - terazosinehydrochloride - terazosin
naropin 5 mg/ml inj. opl. i.thec. amp.
aspen pharma trading ltd. - ropivacaïnehydrochloridemonohydraat - eq. ropivacaïnehydrochloride 5 mg/ml - oplossing voor injectie - 5 mg/ml - ropivacaïnehydrochloridemonohydraat - ropivacaine
myleran 2 mg filmomh. tabl.
aspen pharma trading ltd. - busulfan 2 mg - filmomhulde tablet - 2 mg - busulfan 2 mg - busulfan
xylocaine 5 % zalf
aspen pharma trading ltd. - lidocaïne 50 mg - zalf - 5 % - lidocaïne 50 mg/g - lidocaine
xylocaine gel 2 % urethr. gel
aspen pharma trading ltd. - lidocaïnehydrochloride 20 mg - gel voor urethraal gebruik - 2 % - lidocaïnehydrochloride 20 mg/ml - lidocaine
xylocaine gel 2 % urethr. gel voorgev. spuit
aspen pharma trading ltd. - lidocaïnehydrochloride 20 mg - gel voor urethraal gebruik - 2 % - lidocaïnehydrochloride 20 mg/g - lidocaine
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
cevenfacta
laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorragica - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.
iqymune 100 mg/ml inf. opl. i.v. flac.
laboratoire français du fractionnement et des biotechnologies s.a. - humane normale immunoglobulinen 100 mg/ml - oplossing voor infusie - 100 mg/ml - humane normale immunoglobulinen 100 mg/ml - immunoglobulins, normal human, for intravascular adm.
horse allo 20
centauri biotech sl - allogene equine vet-afgeleide mesenchymale stamcellen - paarden - voor de behandeling van artrose bij volwassen niet-voedselproducerende paarden.